These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 31804689)
1. Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer. Yamaguchi M; Hirata H; Ebi N; Araki J; Seto T; Maruyama R; Akamine S; Inoue Y; Semba H; Sasaki J; Okamoto T Jpn J Clin Oncol; 2020 Mar; 50(3):318-324. PubMed ID: 31804689 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401. Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107 [TBL] [Abstract][Full Text] [Related]
3. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06). Locher C; Pourel N; Le Caer H; Berard H; Auliac JB; Monnet I; Descourt R; Vergnenègre A; Lafay IM; Greillier L; Chouaïd C Lung Cancer; 2018 Jul; 121():25-29. PubMed ID: 29858022 [TBL] [Abstract][Full Text] [Related]
4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
5. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671 [TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer. Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463 [TBL] [Abstract][Full Text] [Related]
7. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197 [TBL] [Abstract][Full Text] [Related]
8. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Juan O; Sánchez-Hernández A; Vázquez S; Casal J; Firvida JL; Aparisi F; Muñoz J; García-Sánchez J; Gironés R; Lázaro M; Giner V Anticancer Res; 2014 Apr; 34(4):1959-66. PubMed ID: 24692732 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421 [TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Costa Rivas M; Huidobro Vence G; Fírvida Pérez JL; Campos Balea B; García Gonzalez J; Lázaro Quintela M; Caeiro Muñoz M; Taboada Valladares B; Castro Gómez JE; Vázquez Estevez S; Afonso Afonso FJ; Azpitarte Raposeiras C; Amenedo Gancedo M; Casal Rubio J Clin Transl Oncol; 2018 Nov; 20(11):1467-1473. PubMed ID: 29696478 [TBL] [Abstract][Full Text] [Related]
12. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration. Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401 [TBL] [Abstract][Full Text] [Related]
13. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial. Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662 [TBL] [Abstract][Full Text] [Related]
14. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer]. Wang J; Pang QS; Wang P; Wang J; Wang W Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691 [TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer. Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970 [TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience. Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402 [TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Provencio M; Majem M; Guirado M; Massuti B; de Las Peñas R; Ortega AL; Dómine M; Marsé R; Sala MÁ; Paredes A; Morán T; Vázquez S; Coves J; Larriba JLG; Sánchez JM; Vicente D; Farré N; Fornos LF; Zapata I; Franco F; Serna-Blasco R; Romero A; Isla D Lung Cancer; 2021 Mar; 153():25-34. PubMed ID: 33453470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]